This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Holder, D. A. Articles by Fallen, E. L. Search for Related Content PubMed PubMed Citation Articles by Holder, D. A. Articles by Fallen, E. L.

Circulation, Vol 55, 541-544, Copyright © 1977 by American Heart Association

ARTICLES

Experience with bretylium tosylate by a hospital cardiac arrest team

DA Holder, AD Sniderman, G Fraser and EL Fallen

The effect of bretylium tosylate (BT) was determined in 27 consecutive cases of resistant ventricular fibrillation (VF) encountered by a hospital cardiac arrest team. The VF was sustained and completely resistant to multiple injections of lidocaine, sequential DC shocks at 400 watt-sec and one or a combination of intravenous propranolol, diphenylhydantoin or procainamide. Following 30 min of sustained cardiac massage, BT (5 mg/kg i.v.) was administered. In 20 patients, VF was terminated within 9-12 min after DC shock. Eight of these patients failed to recover while 12 (44%) of all patients resuscitated survived to be discharged from hospital. Eleven out of 20 (55%) of all patients who had a cardiac arrest outside the CCU were survivors; only one out of seven in the CCU were successfully resuscitated. While receiving maintanance BT post-resuscitation (5 mg/kg i.m. q 8-12 hrs x 48 hrs), half the patients developed hypotension and three required vasopressors and/or fluid replacement. The data indicate that BT is a useful agent in patients with sustained VF refractory to repeated lidocaine injections, some other antiarrhythmic agents, and multiple DC shocks.

This article has been cited by other articles:

				P. R. Kowey, J. H. Levine, J. M. Herre, A. Pacifico, B. D. Lindsay, V. J. Plumb, D. L. Janosik, H. A. Kopelman, and M. M. Scheinman Randomized, Double-Blind Comparison of Intravenous Amiodarone and Bretylium in the Treatment of Patients With Recurrent, Hemodynamically Destabilizing Ventricular Tachycardia or Fibrillation Circulation, December 1, 1995; 92(11): 3255 - 3263. [Abstract] [Full Text]

				Adult Advanced Cardiac Life Support JAMA, October 28, 1992; 268(16): 2199 - 2241. [Abstract] [PDF]

				Standards and Guidelines for Cardiopulmonary Resuscitation (CPR) and Emergency Cardiac Care (ECC) JAMA, June 6, 1986; 255(21): 2905 - 2984. [Abstract] [PDF]

				J. L. Anderson, K. D. Popat, and B. Pitt Paradoxical Ventricular Tachycardia and Fibrillation After Intravenous Bretylium Therapy: Report of Two Cases Arch Intern Med, May 1, 1981; 141(6): 801 - 802. [Abstract] [PDF]

				Standards and Guidelines for Cardiopulmonary Resuscitation (CPR) and Emergency Cardiac Care (ECC) JAMA, August 1, 1980; 244(5): 453 - 509. [Abstract] [PDF]

				R. H. HEISSENBUTTEL and J. T. BIGGER Jr. New Drugs: Bretylium Tosylate: A Newly Available Antiarrhythmic Drug for Ventricular Arrhythmias Ann Intern Med, August 1, 1979; 91(2): 229 - 238. [Abstract] [PDF]